These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29668327)

  • 1. Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors.
    Calcedo R; Chichester JA; Wilson JM
    Hum Gene Ther Methods; 2018 Apr; 29(2):86-95. PubMed ID: 29668327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
    Zhu J; Huang X; Yang Y
    J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
    Costa Verdera H; Kuranda K; Mingozzi F
    Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
    Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of CpG Sequences on Capsid-Specific CD8
    Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
    Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.
    Moskalenko M; Chen L; van Roey M; Donahue BA; Snyder RO; McArthur JG; Patel SD
    J Virol; 2000 Feb; 74(4):1761-6. PubMed ID: 10644347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to adeno-associated virus vectors.
    Zaiss AK; Muruve DA
    Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical models to assess the immunogenicity of AAV vectors.
    Ertl HCJ
    Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate Immune Sensing of Adeno-Associated Virus Vectors.
    Cao D; Byrne BJ; de Jong YP; Terhorst C; Duan D; Herzog RW; Kumar SRP
    Hum Gene Ther; 2024 Jul; 35(13-14):451-463. PubMed ID: 38887999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG-depleted adeno-associated virus vectors evade immune detection.
    Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
    J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.
    Hamilton BA; Wright JF
    Front Immunol; 2021; 12():675897. PubMed ID: 34084173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
    Tse LV; Moller-Tank S; Asokan A
    Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.
    Cramer ML; Shao G; Rodino-Klapac LR; Chicoine LG; Martin PT
    Hum Gene Ther; 2017 Jun; 28(6):493-509. PubMed ID: 28345428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
    McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
    Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies.
    Araujo AE; Bentler M; Perez Garmendia X; Kaleem A; Fabian C; Morgan M; Hacker UT; Büning H
    Hum Gene Ther; 2024 Sep; 35(17-18):586-603. PubMed ID: 39193633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
    Vandamme C; Adjali O; Mingozzi F
    Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
    Masat E; Pavani G; Mingozzi F
    Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.